Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
HOLON, Israel, Feb. 20. 2024 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.